19.2: Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.

One class of bronchodilators includes β₂-adrenoceptor agonists. These agents target the β₂-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β₂-agonists induce relaxation in these muscles, dilating the bronchial passages. This action helps alleviate common asthma symptoms such as wheezing, shortness of breath, and chest tightness.

β₂-adrenoceptor agonists can be further categorized into short-acting β₂-agonists (SABAs) and long-acting β₂-agonists (LABAs). SABAs, including drugs like albuterol and terbutaline (Bricanyl), immediately relieve asthma symptoms. They quickly relax the airway muscles during acute episodes, making them essential for emergencies.

In contrast, LABAs, such as salmeterol (Severent) and formoterol (Symbicort), sustain bronchodilation over an extended period. They are typically used as preventive measures for chronic bronchial conditions, helping to maintain open airways and prevent asthma attacks from occurring.

These medications are often administered via metered-dose inhalers or nebulizers. These devices ensure direct and rapid medication delivery to the respiratory tract, maximizing their effectiveness while minimizing systemic exposure.

Despite their significant benefits in managing asthma, β₂-agonists may also yield undesired systemic effects due to their stimulatory action on β₂-adrenoceptors present in other parts of the body. The most common adverse effect is tremor, which results from stimulating β₂-adrenoceptors in skeletal muscles. Other potential side effects include tachycardia (rapid heart rate) and cardiac dysrhythmias (irregular heart rhythms) resulting from β₂-adrenoceptors stimulation in the heart. Patients must use these medications under medical supervision and promptly report any adverse effects.

Bronchodilators play a pivotal role in asthma management. They ease airway constriction by relaxing bronchial muscles.

One class of bronchodilators includes β₂-adrenoceptor agonists. These agents target the β₂-adrenoceptors on bronchial smooth muscle cells. This induces muscle relaxation, facilitating the bronchial passages' dilation and relieving symptoms such as wheezing, shortness of breath, and chest tightness.

These agonists are categorized as short-acting β₂-agonists or SABAs and long-acting β₂-agonists or LABAs. SABAs, such as albuterol and terbutaline, provide immediate relief by promptly relaxing airway muscles during acute episodes.

Conversely, LABAs, such as salmeterol and formoterol, sustain bronchodilation and serve as preventive measures for chronic bronchial conditions.

These medications are often administered via metered-dose inhalers or nebulizers to ensure direct and rapid delivery to the respiratory tract.

Despite their benefits, β₂-agonists may yield undesired systemic effects. The most common adverse effect is tremor, while potential side effects encompass tachycardia and cardiac dysrhythmia.